Clinical Trials Browser

LMB-100 × Clear all

NCT04027946 2024-04-16

LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

6 enrolled 14 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04840615 2024-02-02

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

Phase 1 Terminated

2 enrolled 14 charts

Other solid neoplasmThoracic

Mesothelioma

NCT05375825 2024-02-02

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

Phase 1 Withdrawn

MyeloidOther solid neoplasmThoracic

Myeloproliferative Disorder, Chronic, with Eosinophilia, Mesothelioma, Malignant, Carcinoma, Pleural Effusion, Malignant

NCT04034238 2023-08-01

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

Phase 1 Completed

19 enrolled 22 charts

Gastrointestinal

Adenocarcinoma, Cholangiocarcinoma

NCT02798536 2022-08-23

Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma

Phase 1 Completed

21 enrolled 19 charts

Other solid neoplasmThoracic

Mesothelioma

NCT02810418 2022-03-15

Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors

Phase 1/2 Completed

40 enrolled 37 charts

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT03644550 2021-12-02

Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma

Phase 2 Terminated

18 enrolled 15 charts

Other solid neoplasmThoracic

Mesothelioma

NCT03436732 2019-11-22

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

Phase 1 Terminated

5 enrolled 12 charts

Other solid neoplasmThoracic

Mesothelioma

NCT02317419 2016-07-26

A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors

Phase 1 Terminated

Neoplasms